Clinical Management of Staphylococcus Aureus Bacteremia

Staphylococcus aureus bacteremia represents a critical bloodstream infection that demands rapid recognition and a coordinated therapeutic approach. Following the detection of S. aureus in blood cultures, clinicians must assess for endovascular involvement, metastatic complications and the presence of an indwelling focus such as a vascular catheter or prosthetic device. Echocardiography is routinely employed to exclude infective endocarditis, while cross-sectional imaging identifies occult abscesses. Empirical therapy must cover both methicillin-susceptible and methicillin-resistant strains, commonly initiating a beta-lactam agent for susceptible isolates and vancomycin or daptomycin for resistant organisms. Antibiotic choice and duration are tailored according to infection complexity: uncomplicated cases typically require two weeks of intravenous therapy, whereas endovascular or deep‐seated infections may necessitate four to six weeks or longer. Source control, including device removal or surgical drainage, is indispensable to prevent relapse. Follow-up blood cultures verify clearance, and transition to oral agents may be considered in selected patients. A multidisciplinary, often infectious disease-led, care bundle has been shown to improve adherence to best practices, reduce mortality and shorten hospital stays. Globally, S. aureus bacteremia remains associated with substantial morbidity, driving efforts to refine diagnostic pathways, optimise antimicrobial stewardship and implement electronic support tools that standardise decision-making, especially in resource-limited settings.

Research from Nature Portfolio

A large multicentre study conducted in tertiary hospitals in China compared outcomes among patients with methicillin-resistant S. aureus, methicillin-susceptible S. aureus and those without S. aureus infection. After propensity score matching, MRSA infection was associated with significantly increased hospital costs—ranging from USD 3,200 to USD 9,600—and extended lengths of stay by six to fourteen days. The attributable in-hospital mortality for MRSA ranged up to 3.6 per cent. Comparison with MSSA revealed higher costs and prolonged admission among survivors, but mortality rates were similar. These findings quantify the economic and clinical burden of MRSA, underscoring the need for targeted infection-control strategies and resource allocation to improve patient outcomes.

Clinical Management of Staphylococcus Aureus Bacteremia publication trend

The graph below shows the total number of articles in clinical management of staphylococcus aureus bacteremia across all publications each year (not limited to Nature Index journals).

Technical terms

Staphylococcus aureus bacteremia: presence of S. aureus bacteria in the bloodstream, often leading to systemic infection.
Methicillin-resistant Staphylococcus aureus (MRSA): strains of S. aureus that are resistant to methicillin and related beta-lactam antibiotics.
Source control: physical removal or drainage of an infectious nidus, such as catheter extraction or abscess drainage.
18F-FDG-PET/CT: a hybrid imaging technique using a radiolabelled glucose analogue to localise metabolically active infectious foci.
Infectious disease consultation: expert review by an infectious diseases specialist to guide diagnostic evaluation and antimicrobial therapy.

References

1. Leveraging electronic medical records to evaluate a computerized decision support system for staphylococcus bacteremia. npj Digital Medicine (2025).
2. Advanced Imaging for Detection of Foci of Infection in Staphylococcus aureus Bacteremia- Can a Scan Save Lives?. Seminars in Nuclear Medicine (2023).
3. Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study. Clinical Infectious Diseases (2019).
4. Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. PLOS ONE (2017).
5. Impact of routine bedside infectious disease consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adults. Clinical Microbiology and Infection (2015).
6. Clinical and economic impact of methicillin-resistant Staphylococcus aureus: a multicentre study in China. Scientific Reports (2020).